Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats

European Journal of Pharmacology

Volumn 514, Issue 1, 2005, Pages 25-34

  Pietraszek, Małgorzata ^a,e   Sukhanov, Ilia ^b   Maciejak, Piotr ^d   Szyndler, Janusz ^c   Gravius, Andreas ^a   Wisłowska, Aleksandra ^c   Płaźnik, Adam ^d   Bespalov, Anton Y ^b   Danysz, Wojciech ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^e INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Anxiety; Contextual fear conditioning; Fear potentiated startle; Geller Seifter test; Group I mGlu receptor; Plus maze

Indexed keywords

(3 ETHYL 2 METHYLQUINOLIN 6 YL)(4 METHOXYCYCLOHEXYL)METHANONE METHANESULFONATE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; CHLORDIAZEPOXIDE; DIAZEPAM; METABOTROPHIC GLUTAMATE RECEPTOR 1 ANTAGONIST; METABOTROPHIC GLUTAMATE RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MIDAZOLAM; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; ATTENUATION; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; FEAR; FREEZING; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; CHLORDIAZEPOXIDE; CONDITIONING, OPERANT; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MAZE LEARNING; MIDAZOLAM; PUNISHMENT; PYRIDINES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; STARTLE REACTION; THIAZOLES;

EID: 18844364756     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.03.028     Document Type: Article

References (43)

1. P. Benquet, C.E. Gee, and U. Gerber Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes J. Neurosci. 22 2002 9679 9686
2. J. Brodkin, M. Bradbury, C. Busse, N. Warren, L.J. Bristow, and M.A. Varney Reduced stress-induced hyperthermia in mGluR5 knockout mice Eur. J. Neurosci. 16 2002 2241 2244
3. J. Brodkin, C. Busse, S.J. Sukoff, and M.A. Varney Anxiolytic-like activity of the mGluR5 antagonist MPEP. A comparison with diazepam and buspirone Pharmacol. Biochem. Behav. 73 2002 359 366
4. C.S. Busse, J. Brodkin, D. Tattersall, J.J. Anderson, N. Warren, L. Tehrani, L.J. Bristow, M.A. Varney, and N.D. Cosford The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4- yl)ethynyl]pyridine (MTEP) in rodent models of anxiety Neuropsychopharmacology 29 2004 1971 1979
5. E. Chojnacka-Wojcik, A. Klodzinska, and A. Pilc Glutamate receptor ligands as anxiolytics Curr. Opin. Investig. Drugs 8 2001 1112 1119
6. N.D. Cosford, L. Tehrani, J. Roppe, E. Schweiger, N.D. Smith, J. Anderson, L. Bristow, J. Brodkin, X. Jiang, I. McDonald, S. Rao, M. Washburn, and M.A. Varney 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity J. Med. Chem. 46 2003 204 206
7. W. Danysz, M. Pietraszek, A. Gravius, I.M. Sukhanov, A.Y. Bespalov, P. Maciejak, J. Szyndler, and A. Plaznik Activity of mGluR1 and GluR5 metabotropic glutamate receptor antagonists in animal models of anxiety Soc. Neurosci. Abstr. 30 2004 1156
8. M. Davis The role of the amygdala in fear-potentiated startle-implications for animal models of anxiety Trends Pharmacol. Sci. 13 1992 35 41
9. G.R. Dawson, and M.D. Tricklebank Use of the elevated plus maze in the search for novel anxiolytic agents Trends Pharmacol. Sci. 16 1995 33 36
10. A.J. Doherty, M.J. Palmer, J.M. Henley, G.L. Collingridge, and D.E. Jane (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus Neuropharmacology 36 1997 265 267
11. M. Fendt, and M.S. Fanselow The neuroanatomical and neurochemical basis of conditioned fear Neurosci. Biobehav. Rev. 23 1999 743 760
12. M. Fendt, and S. Schmid Metabotropic glutamate receptors are involved in amygdaloid plasticity Eur. J. Neurosci. 15 2002 1535 1541
13. F. Gasparini, K. Lingenhohl, N. Stoehr, P.J. Flor, M. Heinrich, I. Vranesic, M. Biollaz, H. Allgeier, R. Heckendorn, S. Urwyler, M.A. Varney, E.C. Johnson, S.D. Hess, S.P. Rao, A.I. Sacaan, E.M. Santori, G. Velicelebi, and R. Kuhn 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist Neuropharmacology 38 1999 1493 1503
14. A. Gravius, M. Pietraszek, D. Schäfer, W.J. Schmidt, and W. Danysz Effects of mGlu1 and mGlu5 receptor antagonists on negatively reinforced learning Behav. Pharmacol. 16 2005 113 121
15. J.S. Han, and V. Neugebauer mGluR1 and mGluR5 antagonists in the amygdala inhibit different components of audible and ultrasonic vocalizations in a model of arthritic pain Pain 113 2005 211 222
16. C.A. Heidbreder, M. Bianchi, L.P. Lacroix, S. Faedo, E. Perdona, R. Remelli, P. Cavanni, and F. Crespi Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo Synapse 50 2003 269 276
17. V. Heidinger, P. Manzerra, X.Q. Wang, U. Strasser, S.P. Yu, D.W. Choi, and M.M. Behrens Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the pyk2/src-family kinase pathway in cortical neurons J. Neurosci. 22 2002 5452 5461
18. A. Klodzinska, E. Tatarczynska, E. Chojnacka-Wojcik, G. Nowak, N.D. Cosford, and A. Pilc Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling Neuropharmacology 47 2004 342 350
19. A. Klodzinska, E. Tatarczynska, K. Stachowicz, and E. Chojnacka-Wojcik The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist J. Physiol. Pharmacol. 55 2004 113 126
20. A.S.J. Lesage, F. Bischoff, L. Van Beijsterveldt, T. Meert, T. Steckler, and D. Ashton Novel, centrally active mGlu1 antagonists: in vitro and in vivo pharmacology Neuropharmacology 43 2002 295
21. P. Maciejak, E. Taracha, M. Lehner, J. Szyndler, A. Bidzinski, A. Skorzewska, A. Wislowska, M. Zienowicz, and A. Plaznik Hippocampal mGluR1 and consolidation of contextual fear conditioning Brain Res. Bull. 62 2003 39 45
22. G. Mannaioni, M.J. Marino, O. Valenti, S.F. Traynelis, and P.J. Conn Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function J. Neurosci. 21 2001 5925 5934
23. F. Moroni, G. Lombardi, C. Thomsen, P. Leonardi, S. Attucci, F. Peruginelli, S.A. Torregrossa, D.E. PellegriniGiampietro, R. Luneia, and R. Pellicciari Pharmacological characterization of 1-aminoindan-1,5-dicarboxylic acid, a potent mGluR1 antagonist J. Pharmacol. Exp. Ther. 281 1997 721 729
24. F. Nicoletti, J.T. Wroblewski, A. Novelli, H. Alho, A. Guidotti, and E. Costa The activation of inositol phospholipid metabolism as a signal-transducing system for excitatory amino acids in primary cultures of cerebellar granule cells J. Neurosci. 6 1986 1905 1911
25. R. Pellicciari, and G. Costantino Metabotropic G-protein-coupled glutamate receptors as therapeutic targets Curr. Opin. Chem. Biol. 3 1999 433 440
26. A. Pilc, A. Klodzinska, P. Branski, G. Nowak, A. Palucha, B. Szewczyk, E. Tatarczynska, E. Chojnacka-Wojcik, and J.M. Wieronska Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats Neuropharmacology 43 2002 181 187
27. A. Plaznik, W. Palejko, M. Nazar, and M. Jessa Effects of antagonists at the NMDA receptor complex in two models of anxiety Eur. Neuropsychopharmacol. 4 1994 503 512
28. 2 + release and inward currents in hippocampal CA1 pyramidal neurons Neuropharmacology 46 2004 1057 1069
29. G. Riedel, G. Casabona, B. Platt, E.M. Macphail, and F. Nicoletti Fear conditioning-induced time- and subregion-specific increase in expression of mGlu5 receptor protein in rat hippocampus Neuropharmacology 39 2000 1943 1951
30. S.M. Rodrigues, E.P. Bauer, C.R. Farb, G.E. Schafe, and J.E. LeDoux The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala J. Neurosci. 22 2002 5219 5229
31. B. Schulz, M. Fendt, F. Gasparini, K. Lingenhohl, R. Kuhn, and M. Koch The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)- pyridine (MPEP) blocks fear conditioning in rats Neuropharmacology 41 2001 1 7
32. R. Shigemoto, S. Nomura, H. Ohishi, H. Sugihara, S. Nakanishi, and N. Mizuno Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain Neurosci. Lett. 163 1993 53 57
33. R. Shigemoto, A. Kinoshita, E. Wada, S. Nomura, H. Ohishi, M. Takada, P.J. Flor, A. Neki, T. Abe, S. Nakanishi, and N. Mizuno Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus J. Neurosci. 17 1997 7503 7522
34. F. Sladeczek, J.P. Pin, M. Recasens, J. Bockaert, and S. Weiss Glutamate stimulates inositol phosphate formation in striatal neurons Nature 317 1985 717 719
35. G.N. Smagin, D. Song, J. Doherty, and L. Mrzljak Attenuation of stress-induced neurochemical and behavioral responses by glutamate 5 receptor (mGluR5) antagonist MTEP Soc. Neurosci. Abstr. 30 2004 115.10
36. W.P. Spooren, A. Vassout, H.C. Neijt, R. Kuhn, F. Gasparini, S. Roux, R.D. Porsolt, and C. Gentsch Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents J. Pharmacol. Exp. Ther. 295 2000 1267 1275
37. W.P. Spooren, P. Schoeffter, F. Gasparini, R. Kuhn, and C. Gentsch Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608) Eur. J. Pharmacol. 435 2002 161 170
38. W. Spooren, T. Ballard, F. Gasparini, M. Amalric, V. Mutel, and R. Schreiber Insight into the function of group I and group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders Behav. Pharmacol. 14 2003 257 277
39. T. Steckler, N. Aerts, H. Van Craenendonck, H. Lavreysen, T. Meert, and A. Lesage Effects of mGlu1 receptor antagonism on anxiety-related behaviour in the rat lick suppression test Soc. Neurosci. Abstr. 29 2003 521.17
40. E. Tatarczynska, A. Klodzinska, E. Chojnacka-Wojcik, A. Palucha, F. Gasparini, R. Kuhn, and A. Pilc Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist Br. J. Pharmacol. 132 2001 1423 1430
41. E. Tatarczynska, A. Klodzinska, B. Kroczka, E. Chojnacka-Wojcik, and A. Pilc The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration Psychopharmacology 158 2001 94 99
42. O. Valenti, P.J. Conn, and M.J. Marino Distinct physiological roles of the Gq-coupled metabotropic glutamate receptors co-expressed in the same neuronal populations J. Cell Physiol. 191 2002 125 137
43. J.M. Wieronska, M. Smialowska, P. Branski, F. Gasparini, A. Klodzinska, B. Szewczyk, A. Palucha, E. Chojnacka-Wojcik, and A. Pilc In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling Neuropsychopharmacology 29 2004 514 521